基因型耐药检测改善了喀麦隆一组青少年的抗逆转录病毒治疗结果:妊娠前期的影响

IF 0.6 Q4 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Journal of Public Health in Africa Pub Date : 2023-10-01 eCollection Date: 2023-10-31 DOI:10.4081/jphia.2023.2612
Willy LE Roi Togna Pabo, Debimeh Njume, Roland Ndip Ndip, Désiré Takou, Maria-Mercedes Santoro, Collins Chenwi, Grace Beloumou, Ezechiel Ngoufack Jagni Semengue, Alex Durand Nka, Aude Christelle Ka'e, Georges Teto, Beatrice Dambaya, Sandrine Djupsa, Raymond Babila Nyasa, Davy Hyacinthe Gouissi Anguechia, Cedric Kamta, Lionel Bala, Virginie Lambo, Samuel Martin Sosso, Vittorio Colizzi, Carlo Federico Perno, Joseph Fokam, Alexis Ndjolo
{"title":"基因型耐药检测改善了喀麦隆一组青少年的抗逆转录病毒治疗结果:妊娠前期的影响","authors":"Willy LE Roi Togna Pabo, Debimeh Njume, Roland Ndip Ndip, Désiré Takou, Maria-Mercedes Santoro, Collins Chenwi, Grace Beloumou, Ezechiel Ngoufack Jagni Semengue, Alex Durand Nka, Aude Christelle Ka'e, Georges Teto, Beatrice Dambaya, Sandrine Djupsa, Raymond Babila Nyasa, Davy Hyacinthe Gouissi Anguechia, Cedric Kamta, Lionel Bala, Virginie Lambo, Samuel Martin Sosso, Vittorio Colizzi, Carlo Federico Perno, Joseph Fokam, Alexis Ndjolo","doi":"10.4081/jphia.2023.2612","DOIUrl":null,"url":null,"abstract":"<p><p>Acquired drug resistance (ADR) is common among adolescents living with perinatal HIV (APHI) in sub-Saharan Africa (SSA). Personalized management has the potential to improve pediatric antiretroviral therapy (ART), even in the presence of long-term treatment and HIV-1 subtype diversity. We sought to evaluate the effect of HIV-1 mutational profiling on immuno-virological response and ADR among APHI. A cohort-study was conducted from 2018-2020 among 311 APHI receiving ART in Cameroon. Clinical, immunological and virological responses were measured at enrolment (T1), 6-months (T2) and 12-months (T3). Immunological failure (IF: CD4 #x003C;250 cells/mm<sup>3</sup>), VF (viremia ≥1,000 copies/ml), and ADR were analyzed, with P#x003C;0.05 considered significant. Mean age was 15(±3) years; male-female ratio was 1:1; median [IQR] ART-duration was 36[21-81] months. At T1, T2, and T3 respectively, adherence-level was 66.4, 58.3 and 66.5%; 14 viral clades were found, driven by CRF02_AG (58.6%); ADR-mutations favored increased switch to second-line ART (16.1, 31.2, and 41.9%, P#x003C;0.0001). From T1-T3 respectively, there were declining rates of IF (25.5, 18.9, and 9.83%, P#x003C;0.0001), VF (39.7, 39.9, and 28.2%, P=0.007), and HIVDR (96.4, 91.7, and 85.0%, P=0.099). Predictors of ADR were being on first-line ART (P=0.045), high viremia at enrolment (AOR=12.56, P=0.059), and IF (AOR=5.86, P=0.010). Of note, optimized ART guided by mutational profile (AOR=0.05, P=0.002) was protective. Moreover, full Tenofovir+Lamivudine+Dolutegravir efficacy was predicted in 77 and 62% of APHI respectively after first- and second-line failure. Among APHI in this SSA setting, viral mutational profiling prompts the use of optimized Dolutegravir-based ART regimens, leading to improved immuno-virological response and declining ADR burdens. Thus, implementing personalized HIV medicine in this vulnerable population would substantially improve ART response and the achievement of the 95-95-95 goals in these underserved populations.</p>","PeriodicalId":44723,"journal":{"name":"Journal of Public Health in Africa","volume":"14 10","pages":"2612"},"PeriodicalIF":0.6000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658463/pdf/","citationCount":"0","resultStr":"{\"title\":\"Genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in Cameroon: Implications in the dolutegravir-era.\",\"authors\":\"Willy LE Roi Togna Pabo, Debimeh Njume, Roland Ndip Ndip, Désiré Takou, Maria-Mercedes Santoro, Collins Chenwi, Grace Beloumou, Ezechiel Ngoufack Jagni Semengue, Alex Durand Nka, Aude Christelle Ka'e, Georges Teto, Beatrice Dambaya, Sandrine Djupsa, Raymond Babila Nyasa, Davy Hyacinthe Gouissi Anguechia, Cedric Kamta, Lionel Bala, Virginie Lambo, Samuel Martin Sosso, Vittorio Colizzi, Carlo Federico Perno, Joseph Fokam, Alexis Ndjolo\",\"doi\":\"10.4081/jphia.2023.2612\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Acquired drug resistance (ADR) is common among adolescents living with perinatal HIV (APHI) in sub-Saharan Africa (SSA). Personalized management has the potential to improve pediatric antiretroviral therapy (ART), even in the presence of long-term treatment and HIV-1 subtype diversity. We sought to evaluate the effect of HIV-1 mutational profiling on immuno-virological response and ADR among APHI. A cohort-study was conducted from 2018-2020 among 311 APHI receiving ART in Cameroon. Clinical, immunological and virological responses were measured at enrolment (T1), 6-months (T2) and 12-months (T3). Immunological failure (IF: CD4 #x003C;250 cells/mm<sup>3</sup>), VF (viremia ≥1,000 copies/ml), and ADR were analyzed, with P#x003C;0.05 considered significant. Mean age was 15(±3) years; male-female ratio was 1:1; median [IQR] ART-duration was 36[21-81] months. At T1, T2, and T3 respectively, adherence-level was 66.4, 58.3 and 66.5%; 14 viral clades were found, driven by CRF02_AG (58.6%); ADR-mutations favored increased switch to second-line ART (16.1, 31.2, and 41.9%, P#x003C;0.0001). From T1-T3 respectively, there were declining rates of IF (25.5, 18.9, and 9.83%, P#x003C;0.0001), VF (39.7, 39.9, and 28.2%, P=0.007), and HIVDR (96.4, 91.7, and 85.0%, P=0.099). Predictors of ADR were being on first-line ART (P=0.045), high viremia at enrolment (AOR=12.56, P=0.059), and IF (AOR=5.86, P=0.010). Of note, optimized ART guided by mutational profile (AOR=0.05, P=0.002) was protective. Moreover, full Tenofovir+Lamivudine+Dolutegravir efficacy was predicted in 77 and 62% of APHI respectively after first- and second-line failure. Among APHI in this SSA setting, viral mutational profiling prompts the use of optimized Dolutegravir-based ART regimens, leading to improved immuno-virological response and declining ADR burdens. Thus, implementing personalized HIV medicine in this vulnerable population would substantially improve ART response and the achievement of the 95-95-95 goals in these underserved populations.</p>\",\"PeriodicalId\":44723,\"journal\":{\"name\":\"Journal of Public Health in Africa\",\"volume\":\"14 10\",\"pages\":\"2612\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2023-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658463/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Public Health in Africa\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/jphia.2023.2612\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/10/31 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Public Health in Africa","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/jphia.2023.2612","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/31 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

摘要

获得性耐药(ADR)在撒哈拉以南非洲(SSA)感染围产期艾滋病毒(APHI)的青少年中很常见。即使存在长期治疗和HIV-1亚型多样性,个性化管理也有可能改善儿科抗逆转录病毒治疗(ART)。我们试图评估HIV-1突变谱对APHI患者免疫病毒学反应和不良反应的影响。2018-2020年,在喀麦隆接受抗逆转录病毒治疗的311名APHI患者中进行了一项队列研究。在入组(T1)、6个月(T2)和12个月(T3)时测量临床、免疫学和病毒学应答。分析免疫功能衰竭(IF: CD4 #x003C;250个细胞/mm3)、VF(病毒血症≥1000拷贝/ml)、不良反应(ADR), P#x003C;0.05认为差异有统计学意义。平均年龄15(±3)岁;男女比例为1:1;中位[IQR] art持续时间为36[21-81]个月。在T1、T2和T3时,依从水平分别为66.4、58.3%和66.5%;共发现14个病毒分支,由CRF02_AG驱动(58.6%);不良反应突变倾向于增加转向二线抗逆转录病毒治疗(16.1%、31.2和41.9%,P#x003C;0.0001)。从T1-T3, IF(25.5%、18.9%、9.83%,P= 0.0001)、VF(39.7%、39.9%、28.2%,P=0.007)和HIVDR(96.4、91.7、85.0%,P=0.099)分别下降。不良反应的预测因子为一线抗逆转录病毒治疗(P=0.045)、入组时高病毒血症(AOR=12.56, P=0.059)和干扰素(AOR=5.86, P=0.010)。值得注意的是,以突变谱为指导的优化ART (AOR=0.05, P=0.002)具有保护作用。此外,一线和二线治疗失败后,替诺福韦+拉米夫定+多鲁替韦的疗效分别为77%和62%。在这种SSA环境下的APHI中,病毒突变分析提示使用优化的基于dolutegravirt的ART方案,从而改善免疫病毒学反应并降低不良反应负担。因此,在这些弱势人群中实施个性化的艾滋病毒药物将大大改善抗逆转录病毒治疗的反应,并在这些服务不足的人群中实现95-95-95目标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in Cameroon: Implications in the dolutegravir-era.

Acquired drug resistance (ADR) is common among adolescents living with perinatal HIV (APHI) in sub-Saharan Africa (SSA). Personalized management has the potential to improve pediatric antiretroviral therapy (ART), even in the presence of long-term treatment and HIV-1 subtype diversity. We sought to evaluate the effect of HIV-1 mutational profiling on immuno-virological response and ADR among APHI. A cohort-study was conducted from 2018-2020 among 311 APHI receiving ART in Cameroon. Clinical, immunological and virological responses were measured at enrolment (T1), 6-months (T2) and 12-months (T3). Immunological failure (IF: CD4 #x003C;250 cells/mm3), VF (viremia ≥1,000 copies/ml), and ADR were analyzed, with P#x003C;0.05 considered significant. Mean age was 15(±3) years; male-female ratio was 1:1; median [IQR] ART-duration was 36[21-81] months. At T1, T2, and T3 respectively, adherence-level was 66.4, 58.3 and 66.5%; 14 viral clades were found, driven by CRF02_AG (58.6%); ADR-mutations favored increased switch to second-line ART (16.1, 31.2, and 41.9%, P#x003C;0.0001). From T1-T3 respectively, there were declining rates of IF (25.5, 18.9, and 9.83%, P#x003C;0.0001), VF (39.7, 39.9, and 28.2%, P=0.007), and HIVDR (96.4, 91.7, and 85.0%, P=0.099). Predictors of ADR were being on first-line ART (P=0.045), high viremia at enrolment (AOR=12.56, P=0.059), and IF (AOR=5.86, P=0.010). Of note, optimized ART guided by mutational profile (AOR=0.05, P=0.002) was protective. Moreover, full Tenofovir+Lamivudine+Dolutegravir efficacy was predicted in 77 and 62% of APHI respectively after first- and second-line failure. Among APHI in this SSA setting, viral mutational profiling prompts the use of optimized Dolutegravir-based ART regimens, leading to improved immuno-virological response and declining ADR burdens. Thus, implementing personalized HIV medicine in this vulnerable population would substantially improve ART response and the achievement of the 95-95-95 goals in these underserved populations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Public Health in Africa
Journal of Public Health in Africa PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
自引率
0.00%
发文量
82
审稿时长
10 weeks
期刊介绍: The Journal of Public Health in Africa (JPHiA) is a peer-reviewed, academic journal that focuses on health issues in the African continent. The journal editors seek high quality original articles on public health related issues, reviews, comments and more. The aim of the journal is to move public health discourse from the background to the forefront. The success of Africa’s struggle against disease depends on public health approaches.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信